Propanc Biopharma Inc PPCB
News
-
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
-
CORRECTION — Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
-
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
-
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
-
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
-
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
-
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
-
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Trading Information
- Previous Close Price
- $2.43
- Day Range
- $2.19–2.25
- 52-Week Range
- $2.19–360.00
- Bid/Ask
- $2.06 / $2.23
- Shares Outstanding
- 1.03M
- Market Cap
- $2.07M
- Volume/Avg
- 37,100 / 181,228
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.propanc.com
Valuation
|
Metric
|
PPCB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.09 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PPCB
Financial Strength
|
Metric
|
PPCB
|
|---|---|
Quick Ratio | 0.25 |
Current Ratio | 2.55 |
Interest Coverage | −42.81 |
Quick Ratio
PPCB
Profitability
|
Metric
|
PPCB
|
|---|---|
Return on Assets (Normalized) | −65.17% |
Return on Equity (Normalized) | −89.79% |
Return on Invested Capital (Normalized) | −77.81% |
Return on Assets
PPCB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<>KwMj | LOCK|V#$? | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|cp^WLGT | LOCK|v<#@J | $84B | |||
| Moderna Inc
MRNA
| LOCK|!LZ?pFR | LOCK|z%@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|W!s!&< | LOCK|QJm | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pFK^<PR | LOCK|?P! | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|St!D!@d | LOCK|%yZk | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%$!#>mSd | LOCK|ZTwvp | $29B | |||
| Incyte Corp
INCY
| LOCK|$#TCm% | LOCK|Dlb | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@FBm%L | LOCK|Sy | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|m<SJ%% | LOCK|bF | $14B |
United States